Moreover, the 36-month beta value for CRVS is 0.57. Analysts have varying opinions on the stock, with 5 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CRVS is 49.68M and currently, short sellers hold a 10.75% of that float. On May 02, 2025, CRVS’s average trading volume was 723.43K shares.
CRVS) stock’s latest price update
Corvus Pharmaceuticals Inc (NASDAQ: CRVS)’s stock price has soared by 3.86 in relation to previous closing price of 3.52. Nevertheless, the company has seen a gain of 0.71% in its stock price over the last five trading days. globenewswire.com reported 2025-04-23 that Data from Cohorts 1-3 of trial to be presented in an oral session and poster at the Society for Investigative Dermatology (SID) 2025 Annual Meeting
CRVS’s Market Performance
CRVS’s stock has risen by 0.71% in the past week, with a monthly rise of 13.89% and a quarterly drop of -31.79%. The volatility ratio for the week is 5.53% while the volatility levels for the last 30 days are 7.97% for Corvus Pharmaceuticals Inc. The simple moving average for the past 20 days is 11.87% for CRVS’s stock, with a -29.95% simple moving average for the past 200 days.
Analysts’ Opinion of CRVS
Many brokerage firms have already submitted their reports for CRVS stocks, with H.C. Wainwright repeating the rating for CRVS by listing it as a “Buy.” The predicted price for CRVS in the upcoming period, according to H.C. Wainwright is $11 based on the research report published on January 02, 2025 of the current year 2025.
Oppenheimer, on the other hand, stated in their research note that they expect to see CRVS reach a price target of $7. The rating they have provided for CRVS stocks is “Outperform” according to the report published on August 18th, 2023.
Jefferies gave a rating of “Buy” to CRVS, setting the target price at $8 in the report published on December 01st of the previous year.
CRVS Trading at -1.85% from the 50-Day Moving Average
After a stumble in the market that brought CRVS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -63.44% of loss for the given period.
Volatility was left at 7.97%, however, over the last 30 days, the volatility rate increased by 5.53%, as shares surge +21.74% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -17.46% lower at present.
During the last 5 trading sessions, CRVS rose by +0.28%, which changed the moving average for the period of 200-days by +56.22% in comparison to the 20-day moving average, which settled at $3.27. In addition, Corvus Pharmaceuticals Inc saw -31.67% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CRVS starting from Jones William Benton, who purchase 20,000 shares at the price of $1.73 back on May 06 ’24. After this action, Jones William Benton now owns 153,773 shares of Corvus Pharmaceuticals Inc, valued at $34,624 using the latest closing price.
MILLER RICHARD A MD, the President and CEO of Corvus Pharmaceuticals Inc, purchase 577,634 shares at $1.73 during a trade that took place back on May 06 ’24, which means that MILLER RICHARD A MD is holding 577,634 shares at $1,000,000 based on the most recent closing price.
Stock Fundamentals for CRVS
The total capital return value is set at -0.82. Equity return is now at value -174.85, with -108.85 for asset returns.
Based on Corvus Pharmaceuticals Inc (CRVS), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -22.66. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is -87.18.
Currently, EBITDA for the company is -27.55 million with net debt to EBITDA at 0.28. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.54.
Conclusion
To wrap up, the performance of Corvus Pharmaceuticals Inc (CRVS) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
